DIA Middle East Regulatory Conference

This session will present the future of innovative medicine and its value from different perspectives: • The innovation in development of new therapies, real world evidence (RWE), novel endpoints (with regard to the development of oncology, neuroscience and diabetes, novel study designs) and benefits of the changes and cooperation between industry and regulators to regulate it; • Sharing a global overview of the research pipeline and provide more insights about what will come next, highlighting clearly the critical role of an efficient regulatory environment; • Discuss the value of innovation in the emerging market (patient quality of life, cost effectiveness, disease burden management/hospitalisation, social impact, competitiveness, etc).